In BrafV600E-driven murine melanomas lacking Cdkn2a, AKT1 activation was shown to enhance brain metastasis, whereas AKT2 and AKT3 had a less pronounced effect [27,32]. This evidence concerns the gene CDKN2A and melanoma.